Visfatin in obese children and adolescents and its association with insulin resistance and metabolic syndrome

References

• Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011;11:85–97.
   PubMed Web of Science ®Google Scholar
• Reilly JJ, Kelly J. Long-term impact of overweight and obesity in childhood and adolescence on morbidity and premature mortality in adulthood: systematic review. Int J Obes (Lond) 2011;35:891–8.
   PubMed Web of Science ®Google Scholar
• Weiss R, Bremer AA, Lustig RH. What is metabolic syndrome, and why are children getting it? Ann N Y Acad Sci 2013;1281:123–40.
   PubMed Web of Science ®Google Scholar
• Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circulation Research 2005;96: 939–49.
   PubMed Web of Science ®Google Scholar
• Stastny J, Bienertova-Vasku J, Vasku A. Visfatin and its role in obesity development. Diabetes Metab Syndr 2012;6: 120–4.
   PubMedGoogle Scholar
• Friebe D, Neef M, Kratzsch J, Erbs S, Dittrich K, Garten A, Petzold-Quinque S, Bluher S, Reinehr T, Stumvoll M, Bluher M, Kiess W, Korner A. Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia 2011;54:1200–11.
   PubMed Web of Science ®Google Scholar
• Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994;14:1431–7.
   PubMed Web of Science ®Google Scholar
• Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD, Marshall JC. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004;113:1318–27.
   PubMed Web of Science ®Google Scholar
• Rongvaux A, Galli M, Denanglaire S, Van Gool F, Dreze PL, Szpirer C, Bureau F, Andris F, Leo O. Nicotinamide phosphoribosyl transferase/pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress. J Immunol 2008; 181:4685–95.
   PubMed Web of Science ®Google Scholar
• Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307:426–30.
   PubMed Web of Science ®Google Scholar
• Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Retraction. Science 2007;318:565.
   PubMed Web of Science ®Google Scholar
• Skop V, Kontrova K, Zidek V, Pravenec M, Kazdova L, Mikulik K, Sajdok J, Zidkova J. Autocrine effects of visfatin on hepatocyte sensitivity to insulin action. Physiol Res 2010;59:615–8.
   PubMed Web of Science ®Google Scholar
• Revollo JR, Korner A, Mills KF, Satoh A, Wang T, Garten A, Dasgupta B, Sasaki Y, Wolberger C, Townsend RR, Milbrandt J, Kiess W, Imai S. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007;6:363–75.
   PubMed Web of Science ®Google Scholar
• Yoshino J, Mills KF, Yoon MJ, Imai S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab 2011;14:528–36.
   PubMed Web of Science ®Google Scholar
• Davutoglu M, Ozkaya M, Guler E, Garipardic M, Gursoy H, Karabiber H, Kilinc M. Plasma visfatin concentrations in childhood obesity: relationships with insulin resistance and anthropometric indices. Swiss Med Wkly 2009;139:22–7.
   PubMed Web of Science ®Google Scholar
• Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 2006;49: 1909–14.
   PubMed Web of Science ®Google Scholar
• Kolsgaard ML, Wangensteen T, Brunborg C, Joner G, Holven KB, Halvorsen B, Aukrust P, Tonstad S. Elevated visfatin levels in overweight and obese children and adolescents with metabolic syndrome. Scand J Clin Lab Invest 2009;69:858–64.
   PubMed Web of Science ®Google Scholar
• Jin H, Jiang B, Tang J, Lu W, Wang W, Zhou L, Shang W, Li F, Ma Q, Yang Y, Chen M. Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol. Diabetes Res Clin Pract 2008;79:412–8.
   PubMed Web of Science ®Google Scholar
• Cook S, Auinger P, Huang TT. Growth curves for cardio-metabolic risk factors in children and adolescents. J Pediatr 2009;155:S6.e15–26.
   Google Scholar
• Zimmet P, Alberti G, Kaufman F, Tajima N, Silink M, Arslanian S, Wong G, Bennett P, Shaw J, Caprio S. The metabolic syndrome in children and adolescents. Lancet 2007;369:2059–61.
   PubMed Web of Science ®Google Scholar
• Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. Endocr Rev 1985;6:45–86.
   PubMed Web of Science ®Google Scholar
• Keskin M, Kurtoglu S, Kendirci M, Atabek ME, Yazici C. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 2005;115:e500–3.
   PubMed Web of Science ®Google Scholar
• Biro FM, Wien M. Childhood obesity and adult morbidities. Am J Clin Nutr 2010;91:1499S–505S.
   PubMed Web of Science ®Google Scholar
• Araki S, Dobashi K, Kubo K, Kawagoe R, Yamamoto Y, Kawada Y, Asayama K, Shirahata A. Plasma visfatin concentration as a surrogate marker for visceral fat accumulation in obese children. Obesity (Silver Spring) 2008; 16:384–8.
   PubMed Web of Science ®Google Scholar
• Taskesen D, Kirel B, Us T. Serum visfatin levels, adiposity and glucose metabolism in obese adolescents. J Clin Res Pediatr Endocrinol 2012;4:76–81.
   PubMed Web of Science ®Google Scholar
• Belo VA, Luizon MR, Lacchini R, Miranda JA, Lanna CM, Souza-Costa DC, Tanus-Santos JE. The effects of NAMPT haplotypes and metabolic risk factors on circulating visfatin/NAMPT levels in childhood obesity. Int J Obes (Lond) 2013;39:130–5.
   PubMed Web of Science ®Google Scholar
• Martos-Moreno GA, Kratzsch J, Korner A, Barrios V, Hawkins F, Kiess W, Argente J. Serum visfatin and vaspin levels in prepubertal children: effect of obesity and weight loss after behavior modifications on their secretion and relationship with glucose metabolism. Int J Obes (Lond) 2011;35:1355–62.
   PubMed Web of Science ®Google Scholar
• Morimoto Y, Conroy SM, Ollberding NJ, Kim Y, Lim U, Cooney RV, Franke AA, Wilkens LR, Hernandez BY, Goodman MT, Henderson BE, Kolonel LN, Le Marchand L, Maskarinec G. Ethnic differences in serum adipokine and C-reactive protein levels: the multiethnic cohort. Int J Obes (Lond) 2014;38:1416–22.
   PubMed Web of Science ®Google Scholar
• Kelishadi R, Haghdoost AA, Sadeghirad B, Khajehkazemi R. Trend in the prevalence of obesity and overweight among Iranian children and adolescents: a systematic review and meta-analysis. Nutrition (Burbank, Los Angeles County, Calif.) 2014;30:393–400.
   PubMed Web of Science ®Google Scholar
• Haider DG, Holzer G, Schaller G, Weghuber D, Widhalm K, Wagner O, Kapiotis S, Wolzt M. The adipokine visfatin is markedly elevated in obese children. J Pediatr Gastroenterol Nutr 2006;43:548–9.
   PubMed Web of Science ®Google Scholar
• Mayi TH, Duhem C, Copin C, Bouhlel MA, Rigamonti E, Pattou F, Staels B, Chinetti-Gbaguidi G. Visfatin is induced by peroxisome proliferator-activated receptor gamma in human macrophages. FEBS J 2010;277:3308–20.
   PubMed Web of Science ®Google Scholar
• Liu SW, Qiao SB, Yuan JS, Liu DQ. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf) 2009;71:202–7.
   PubMed Web of Science ®Google Scholar
• Aygun AD, Gungor S, Ustundag B, Gurgoze MK, Sen Y. Proinflammatory cytokines and leptin are increased in serum of prepubertal obese children. Mediators Inflamm 2005;2005:180–3.
   PubMedGoogle Scholar
• Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract 2014;105: 141–50.
   PubMed Web of Science ®Google Scholar
• Li RZ, Ma X, Hu XF, Kang SX, Chen SK, Cianflone K, Lu HL. Elevated visfatin levels in obese children are related to proinflammatory factors. J Pediatr Endocrinol Metab 2013;26:111–8.
   PubMed Web of Science ®Google Scholar
• Montague CT, Prins JB, Sanders L, Digby JE, O’Rahilly S. Depot- and sex-specific differences in human leptin mRNA expression: implications for the control of regional fat distribution. Diabetes 1997;46:342–7.
   PubMed Web of Science ®Google Scholar
• Corgosinho FC, de Piano A, Sanches PL, Campos RM, Silva PL, Carnier J, Oyama LM, Tock L, Tufik S, de Mello MT, Damaso AR. The role of PAI-1 and adiponectin on the inflammatory state and energy balance in obese adolescents with metabolic syndrome. Inflammation 2012;35:944–51.
   PubMed Web of Science ®Google Scholar
• Winer JC, Zern TL, Taksali SE, Dziura J, Cali AM, Wollschlager M, Seyal AA, Weiss R, Burgert TS, Caprio S. Adiponectin in childhood and adolescent obesity and its association with inflammatory markers and components of the metabolic syndrome. J Clin Endocrinol Metab 2006; 91:4415–23.
   PubMed Web of Science ®Google Scholar
• Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, Lee YJ. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006;91:295–9.
   PubMed Web of Science ®Google Scholar
• Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care 2003;26:3153–9.
   PubMed Web of Science ®Google Scholar
• Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev 2011;27:515–27.
   PubMed Web of Science ®Google Scholar
• Olszanecka-Glinianowicz M, Kocelak P, Nylec M, Chudek J, Zahorska-Markiewicz B. Circulating visfatin level and visfatin/insulin ratio in obese women with metabolic syndrome. Arch Med Sci 2012;8:214–8.
   PubMed Web of Science ®Google Scholar